Relay Therapeutics

US · RLAY #2273 by market cap Listed 2020

17.95 -0.79 -4.22%

Live - 5344 symbols - heartbeat 289s ago · 2026-10-08 07:00

Pre-market 17.84 -0.61%

After-hours 17.95 0.00%

Overnight 17.95 0.00%

Market cap: 3.93B
P/E (TTM): -11.51
P/B: 4.42
EPS: -1.61
Div yield: 0.00%
52W pos: 78%

Reader sentiment Are you bullish or bearish on RLAY?

Anonymous reader poll. Unscientific, not investment advice.

About Relay Therapeutics

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Founded: 2015
CEO: Dr. Sanjiv K. Patel, M.B.B.S.,M.D.
Employees: 192
Headquarters: Cambridge, Massachusetts, United States of America
Fiscal year end: 12-31
Website: relaytx.com

Company profile

Exchange: US
Symbol: RLAY
Market-cap rank: #2273
Listing date: 2020-07-16
Market cap: 3.93B
Float cap: 2.61B
Shares out: 219.14M
Float shares: 145.48M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:27 · For reference only, not investment advice and not tailored to your situation.